"MART-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-specific protein that plays a role in the expression, stability, trafficking, and processing of GP100 MELANOMA ANTIGEN, which is critical to the formation of Stage II MELANOSOMES. The protein is used as an antigen marker for MELANOMA cells.
| Descriptor ID |
D058965
|
| MeSH Number(s) |
D12.776.624.301.750 D23.050.285.439.750
|
| Concept/Terms |
MART-1 Antigen- MART-1 Antigen
- Antigen, MART-1
- MART 1 Antigen
- MART1 Antigens
- Antigens, MART1
- MelanA
- Melanoma Antigen Recognized by T-Cells 1
- Melanoma Antigen Recognized by T Cells 1
- MART1 Antigen
- Antigen, MART1
- Melan-A
- Melan A
|
Below are MeSH descriptors whose meaning is more general than "MART-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "MART-1 Antigen".
This graph shows the total number of publications written about "MART-1 Antigen" by people in this website by year, and whether "MART-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 1 | 2 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "MART-1 Antigen" by people in Profiles.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
The accuracy of detecting melanoma on frozen section melanoma antigen recognized by T cells 1 (MART-1) stains and on permanent sections of previously frozen tissue: A prospective cohort study. J Am Acad Dermatol. 2021 Jun; 84(6):1764-1766.
-
Generation and molecular recognition of melanoma-associated antigen-specific human ?d T cells. Sci Immunol. 2018 12 14; 3(30).
-
Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products. J Immunother. 2018 Jun; 41(5):248-259.
-
Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65.
-
Natural killer T cells in advanced melanoma patients treated with tremelimumab. PLoS One. 2013; 8(10):e76829.
-
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov. 2013 Apr; 3(4):418-29.
-
NOD/scid IL-2Rg(null) mice: a preclinical model system to evaluate human dendritic cell-based vaccine strategies in vivo. J Transl Med. 2012 Feb 25; 10:30.
-
Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer Res. 2011 Feb 15; 71(4):1406-17.
-
Pigmented apocrine hidrocystoma of the caruncle. Cornea. 2010 Nov; 29(11):1320-2.